Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

By afschroeder • April 30, 2026

Shachar EK, Silverstein J, Kwan L, Salani R, Karlan BY, Chase DM. Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers? Gynecol Oncol. 2026 Apr 28;209:26-32. doi: 10.1016/j.ygyno.2026.04.011. Epub ahead of print. PMID: 42054783.

Tags: age, antibody drug conjugates, Ethnicity, gynecologic cancer, Hematology/Oncology, Publications, Race, Underrepresented minorities

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond

Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate[...]

Breast Implant-Associated Malignancies: Current Recommendations for Workup and Management

Fracol ME, Miranda RN, Tsao AS, Rodriguez MM, Nastoupil LJ, Young PA, Sherrod AE, LeBlanc DM, Hunsicker LM, Bacchi CE, Gabriel T, Myckatyn TM, Tanaka[...]